Schedule 13D ownership disclosure
Q/C TECHNOLOGIES INC
Common Stock, par value $0.001 per share · CUSIP: 62856X300
Event date: 2025-11-14
- Filing-level shares
- 8,475,368.00
- Percent of class
- 74.00%
- PharmaCyte Biotech, Inc.Reported CIK 0001157075
Shares: 8,475,368.00 · Class: 74.00%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001683168-25-008515
- Form type
- SCHEDULE 13D/A
- Filer
- PharmaCyte Biotech, Inc.
- CIK
- CIK 1157075
- Filed
- Nov 18, 2025
- Reporting period
- Nov 14, 2025
- Description
- Schedule 13D beneficial ownership